Summit Therapeutics Plc Stock Today
| SMMT Stock | USD 18.94 0.26 1.35% |
Performance8 of 100
| Odds Of DistressLess than 8
|
Summit Therapeutics is selling for under 18.94 as of the 28th of November 2024; that is 1.35 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 18.76. Summit Therapeutics has only a 8 % chance of going through financial distress over the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Summit Therapeutics PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of March 2015 | Category Healthcare | Classification Health Care |
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. The company was founded in 2003 and is based in Cambridge, Massachusetts. Summit Therapeu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 737.45 M outstanding shares of which 17.04 M shares are at this time shorted by private and institutional investors with about 6.96 trading days to cover. More on Summit Therapeutics PLC
Moving against Summit Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Summit Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CoCEO | MBA DDS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Jakarta Stock Exchange, Biotech, Israel Wall Street, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSummit Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Summit Therapeutics' financial leverage. It provides some insight into what part of Summit Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summit Therapeutics PLC (SMMT) is traded on NASDAQ Exchange in USA. It is located in 601 Brickell Key Drive, Miami, FL, United States, 33131 and employs 105 people. Summit Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 14.16 B. Summit Therapeutics PLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 737.45 M outstanding shares of which 17.04 M shares are at this time shorted by private and institutional investors with about 6.96 trading days to cover.
Summit Therapeutics PLC currently holds about 121.97 M in cash with (76.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61.
Check Summit Therapeutics Probability Of Bankruptcy
Ownership AllocationSummit Therapeutics PLC shows a total of 737.45 Million outstanding shares. Summit Therapeutics PLC has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 84.36 % of Summit Therapeutics outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Summit Ownership Details
Summit Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| First Trust Advisors L.p. | 2024-06-30 | 788.1 K | |
| Pictet Asset Manangement Sa | 2024-06-30 | 708.6 K | |
| Td Asset Management Inc | 2024-09-30 | 694.7 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 674.2 K | |
| Citadel Advisors Llc | 2024-09-30 | 650.8 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 453.9 K | |
| Balyasny Asset Management Llc | 2024-09-30 | 431.2 K | |
| D. E. Shaw & Co Lp | 2024-09-30 | 402.2 K | |
| Barclays Plc | 2024-06-30 | 387.3 K | |
| Baker Bros Advisors Lp | 2024-09-30 | 24.4 M | |
| Vanguard Group Inc | 2024-09-30 | 10.9 M |
Summit Therapeutics Historical Income Statement
Summit Stock Against Markets
Summit Therapeutics Corporate Management
| Elaine JD | Head Counsel | Profile | |
| Fong Clow | Chief Officer | Profile | |
| Betty Chang | Oncology Research | Profile | |
| Bhaskar Anand | Chief Finance | Profile | |
| Will Black | Head Technology | Profile |
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.